These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Molecular pathobiology of gastrointestinal stromal sarcomas. Corless CL; Heinrich MC Annu Rev Pathol; 2008; 3():557-86. PubMed ID: 18039140 [TBL] [Abstract][Full Text] [Related]
23. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview. Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566 [TBL] [Abstract][Full Text] [Related]
24. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858 [TBL] [Abstract][Full Text] [Related]
25. Get the GIST? An overview of gastrointestinal stromal tumours. Watson GA; Kelly D; Melland-Smith M; Gleeson J; McEntee G; Kelly CM; McCaffrey JA Ir J Med Sci; 2016 May; 185(2):319-26. PubMed ID: 26833487 [TBL] [Abstract][Full Text] [Related]
26. Biomarkers in GIST: partly ready for prime-time use. Blanke CD Clin Cancer Res; 2009 Sep; 15(18):5603-5. PubMed ID: 19737947 [TBL] [Abstract][Full Text] [Related]
27. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193 [TBL] [Abstract][Full Text] [Related]
28. [The diagnostic and predictive role of kit (CD117)]. Dirnhofer S; Zimpfer A; Went P Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459 [TBL] [Abstract][Full Text] [Related]
29. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617 [TBL] [Abstract][Full Text] [Related]
30. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours. Renouf DJ; Wilson L; Blanke CD Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180 [TBL] [Abstract][Full Text] [Related]
31. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695 [TBL] [Abstract][Full Text] [Related]
33. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)]. Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090 [TBL] [Abstract][Full Text] [Related]
34. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246 [TBL] [Abstract][Full Text] [Related]
35. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460 [TBL] [Abstract][Full Text] [Related]
36. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
37. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related]